-- 週五下午晚些時候,醫療保健類股下跌,紐約證券交易所醫療保健指數和道富醫療保健精選行業SPDR ETF (XLV) 均下跌約0.9%。 iShares生物技術ETF (IBB) 下跌0.3%。 在產業新聞方面,《華爾街日報》週五報道稱,唐納德·川普總統已批准解僱美國食品藥品監督管理局局長馬蒂·馬卡里 (Marty Makary) 的計劃。該報本週稍早報導稱,川普近日對馬卡里批准調味電子煙和尼古丁袋耗時過長表示不滿。 公司新聞方面,在周四公佈第一季業績後,Ameriprise將Zoetis (ZTS) 的股票評級從“買入”下調至“持有”,受此影響,Zoetis股價下跌超過5%。瑞銀集團也將Zoetis的目標股價從130美元下調至99美元,傑富瑞集團則從155美元下調至117美元。 Traws Pharma (TRAW) 股價飆漲28%。該公司週五表示,計劃利用其針對負鏈RNA病毒的抗病毒候選藥物組合,開發治療和預防漢他病毒感染的潛在療法。 根據彭博社引述市場研究公司Pharmarack的數據報道,儘管仿製藥大量湧入市場,諾和諾德(NVO)在印度4月份的糖尿病和減肥藥物銷售額仍環比增長40%,這得益於其大幅降價。諾和諾德股價上漲0.5%。 PTC Therapeutics(PTCT)股價上漲超過14%,此前該公司公佈的第一季淨虧損低於預期,總收入也超過了分析師的普遍預期。
Related Articles
Research Alert: CFRA Keeps Buy Opinion On Shares Of American International Group
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $4 to $88, valuing the shares at 11x our 2026 operating EPS estimate of $8.00 (raised today by $0.15) and at 10x our 2027 EPs estimate of $8.90, vs. the one-year average forward multiple of 11x and a peer average of 13x. AIG posted strong Q1 results with operating EPS of $2.11 vs. $1.17 in the prior year, topping our $1.95 estimate and the $1.88 consensus view on improved claim trends. General Insurance net premiums written surged 24% to $5.6B, while underwriting income more than tripled to $774M with the combined ratio improving 850 bps to 87.3% on lower catastrophe losses. Though we caution Q1 results are not likely an annual run-rate, we view AIG as undervalued and believe its ability to produce above-peer underwriting profitability will provide a catalyst for shares to close their valuation gap with peers.
Coreweave Insider Sold Shares Worth $961,839, According to a Recent SEC Filing
Sachin Jain, Chief Operating Officer, on May 06, 2026, sold 7,335 shares in Coreweave (CRWV) for $961,839. Following the Form 4 filing with the SEC, Jain has control over a total of 104,068 Class A common shares of the company, with 104,068 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1769628/000176962826000225/xslF345X05/form4.xml
Coreweave Insider Sold Shares Worth $10,515,594, According to a Recent SEC Filing
Brian M Venturo, Director, Chief Strategy Officer, on May 06, 2026, sold 76,924 shares in Coreweave (CRWV) for $10,515,594. Following the Form 4 filing with the SEC, Venturo has control over a total of 411,446 Class A common shares of the company, with 223,580 shares held directly and 187,866 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1769628/000176962826000226/xslF345X05/form4.xml